JPS58113129A - 変異原性抑制剤 - Google Patents

変異原性抑制剤

Info

Publication number: JPS58113129A
Authority: JP; Japan
Prior art keywords: pyrene; benz; sulfonic acid; pantethein; pantethine
Prior art date: 1981-12-28
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

JP20965481A

Other languages

English (en)

Japanese (ja)

Other versions

JPH0155243B2 (de

Inventor

Yasuko Osawa

大沢　靖子

Saburo Uchikuga

三郎内空閑

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Sogo Pharmaceutical Co Ltd

Original Assignee

Sogo Pharmaceutical Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1981-12-28

Filing date

1981-12-28

Publication date

1983-07-05

1981-12-28 Application filed by Sogo Pharmaceutical Co Ltd filed Critical Sogo Pharmaceutical Co Ltd

1981-12-28 Priority to JP20965481A priority Critical patent/JPS58113129A/ja

1983-07-05 Publication of JPS58113129A publication Critical patent/JPS58113129A/ja

1989-11-22 Publication of JPH0155243B2 publication Critical patent/JPH0155243B2/ja

Status Granted legal-status Critical Current

Links

239000003112 inhibitor Substances 0.000 title claims abstract description 10
238000002703 mutagenesis Methods 0.000 title abstract 2
231100000350 mutagenesis Toxicity 0.000 title abstract 2
150000003839 salts Chemical class 0.000 claims abstract description 12
239000004480 active ingredient Substances 0.000 claims abstract description 8
238000006073 displacement reaction Methods 0.000 claims description 2
239000000126 substance Substances 0.000 abstract description 19
230000007246 mechanism Effects 0.000 abstract description 8
FMMWHPNWAFZXNH-UHFFFAOYSA-N Benz[a]pyrene Chemical compound C1=C2C3=CC=CC=C3C=C(C=C3)C2=C2C3=CC=CC2=C1 FMMWHPNWAFZXNH-UHFFFAOYSA-N 0.000 abstract description 7
230000000711 cancerogenic effect Effects 0.000 abstract description 7
DJWYOLJPSHDSAL-UHFFFAOYSA-N Pantethine Natural products OCC(C)(C)C(O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)C(O)C(C)(C)CO DJWYOLJPSHDSAL-UHFFFAOYSA-N 0.000 abstract description 6
DJWYOLJPSHDSAL-ROUUACIJSA-N pantethine Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)CO DJWYOLJPSHDSAL-ROUUACIJSA-N 0.000 abstract description 6
229960000903 pantethine Drugs 0.000 abstract description 6
235000008975 pantethine Nutrition 0.000 abstract description 6
239000011581 pantethine Substances 0.000 abstract description 6
229910052783 alkali metal Inorganic materials 0.000 abstract description 5
231100000315 carcinogenic Toxicity 0.000 abstract description 5
208000005623 Carcinogenesis Diseases 0.000 abstract description 4
230000036952 cancer formation Effects 0.000 abstract description 4
231100000504 carcinogenesis Toxicity 0.000 abstract description 4
230000002401 inhibitory effect Effects 0.000 abstract description 4
150000001340 alkali metals Chemical class 0.000 abstract description 3
229910052784 alkaline earth metal Inorganic materials 0.000 abstract description 3
235000019658 bitter taste Nutrition 0.000 abstract description 3
244000000626 Daucus carota Species 0.000 abstract description 2
235000002767 Daucus carota Nutrition 0.000 abstract description 2
239000003183 carcinogenic agent Substances 0.000 abstract description 2
150000002009 diols Chemical class 0.000 abstract description 2
238000006735 epoxidation reaction Methods 0.000 abstract description 2
150000001342 alkaline earth metals Chemical group 0.000 abstract 1
239000000825 pharmaceutical preparation Substances 0.000 abstract 1
231100000299 mutagenicity Toxicity 0.000 description 18
230000007886 mutagenicity Effects 0.000 description 18
238000012360 testing method Methods 0.000 description 8
230000000694 effects Effects 0.000 description 6
-1 amine salts Chemical class 0.000 description 5
125000005605 benzo group Chemical group 0.000 description 5
239000003795 chemical substances by application Substances 0.000 description 5
239000000203 mixture Substances 0.000 description 5
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
206010028980 Neoplasm Diseases 0.000 description 4
235000019504 cigarettes Nutrition 0.000 description 4
150000001875 compounds Chemical class 0.000 description 4
239000008187 granular material Substances 0.000 description 4
BBEAQIROQSPTKN-UHFFFAOYSA-N pyrene Chemical compound C1=CC=C2C=CC3=CC=CC4=CC=C1C2=C43 BBEAQIROQSPTKN-UHFFFAOYSA-N 0.000 description 4
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
241000124008 Mammalia Species 0.000 description 3
229910052791 calcium Inorganic materials 0.000 description 3
239000011575 calcium Substances 0.000 description 3
201000011510 cancer Diseases 0.000 description 3
239000003153 chemical reaction reagent Substances 0.000 description 3
239000000796 flavoring agent Substances 0.000 description 3
235000013355 food flavoring agent Nutrition 0.000 description 3
238000000034 method Methods 0.000 description 3
206010007269 Carcinogenicity Diseases 0.000 description 2
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
241000700159 Rattus Species 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
239000002246 antineoplastic agent Substances 0.000 description 2
230000001580 bacterial effect Effects 0.000 description 2
239000012620 biological material Substances 0.000 description 2
231100000260 carcinogenicity Toxicity 0.000 description 2
230000007670 carcinogenicity Effects 0.000 description 2
239000003814 drug Substances 0.000 description 2
GVEPBJHOBDJJJI-UHFFFAOYSA-N fluoranthrene Natural products C1=CC(C2=CC=CC=C22)=C3C2=CC=CC3=C1 GVEPBJHOBDJJJI-UHFFFAOYSA-N 0.000 description 2
235000013305 food Nutrition 0.000 description 2
239000001863 hydroxypropyl cellulose Substances 0.000 description 2
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
239000008101 lactose Substances 0.000 description 2
239000000314 lubricant Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
238000002156 mixing Methods 0.000 description 2
229930014626 natural product Natural products 0.000 description 2
GHOKWGTUZJEAQD-UHFFFAOYSA-N pantothenic acid Chemical compound OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 2
241000894006 Bacteria Species 0.000 description 1
TXVHTIQJNYSSKO-UHFFFAOYSA-N BeP Natural products C1=CC=C2C3=CC=CC=C3C3=CC=CC4=CC=C1C2=C34 TXVHTIQJNYSSKO-UHFFFAOYSA-N 0.000 description 1
244000132059 Carica parviflora Species 0.000 description 1
235000014653 Carica parviflora Nutrition 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
240000001090 Papaver somniferum Species 0.000 description 1
235000008753 Papaver somniferum Nutrition 0.000 description 1
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical class C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
241000277263 Salmo Species 0.000 description 1
241000607142 Salmonella Species 0.000 description 1
241001138501 Salmonella enterica Species 0.000 description 1
239000002253 acid Substances 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
239000003674 animal food additive Substances 0.000 description 1
238000010171 animal model Methods 0.000 description 1
230000003217 anti-cancerogenic effect Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
159000000007 calcium salts Chemical class 0.000 description 1
231100000357 carcinogen Toxicity 0.000 description 1
239000005018 casein Substances 0.000 description 1
BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
235000021240 caseins Nutrition 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
229920002301 cellulose acetate Polymers 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
239000003086 colorant Substances 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
229940099112 cornstarch Drugs 0.000 description 1
238000012258 culturing Methods 0.000 description 1
229960001760 dimethyl sulfoxide Drugs 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
239000010931 gold Substances 0.000 description 1
229910052737 gold Inorganic materials 0.000 description 1
230000003179 granulation Effects 0.000 description 1
238000005469 granulation Methods 0.000 description 1
239000007902 hard capsule Substances 0.000 description 1
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000005556 hormone Substances 0.000 description 1
125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
229910052742 iron Inorganic materials 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
239000000463 material Substances 0.000 description 1
231100000150 mutagenicity / genotoxicity testing Toxicity 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
125000003201 pantothenic acid group Chemical group 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
125000005575 polycyclic aromatic hydrocarbon group Chemical group 0.000 description 1
239000000843 powder Substances 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
230000002265 prevention Effects 0.000 description 1
230000003449 preventive effect Effects 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
239000002994 raw material Substances 0.000 description 1
239000000779 smoke Substances 0.000 description 1
239000007901 soft capsule Substances 0.000 description 1
239000000243 solution Substances 0.000 description 1
239000004071 soot Substances 0.000 description 1
BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
239000003826 tablet Substances 0.000 description 1
235000019640 taste Nutrition 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
231100000820 toxicity test Toxicity 0.000 description 1
239000011782 vitamin Substances 0.000 description 1
229940088594 vitamin Drugs 0.000 description 1
235000013343 vitamin Nutrition 0.000 description 1
229930003231 vitamin Natural products 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Landscapes

Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

JP20965481A 1981-12-28 1981-12-28 変異原性抑制剤 Granted JPS58113129A (ja)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
JP20965481A JPS58113129A (ja)	1981-12-28	1981-12-28	変異原性抑制剤

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
JP20965481A JPS58113129A (ja)	1981-12-28	1981-12-28	変異原性抑制剤

Publications (2)

Publication Number	Publication Date
JPS58113129A true JPS58113129A (ja)	1983-07-05
JPH0155243B2 JPH0155243B2 (de)	1989-11-22

Family

ID=16576380

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP20965481A Granted JPS58113129A (ja)	1981-12-28	1981-12-28	変異原性抑制剤

Country Status (1)

Country	Link
JP (1)	JPS58113129A (de)

1981
- 1981-12-28 JP JP20965481A patent/JPS58113129A/ja active Granted

Also Published As

Publication number	Publication date
JPH0155243B2 (de)	1989-11-22

Publication	Publication Date	Title
CA2078028C (en)	2003-04-29	A tramadol n-oxide material, enantiomers and compositions thereof, and their use
US5041425A (en)	1991-08-20	Antitumor agent
USRE36831E (en)	2000-08-22	Iron-pyridone complexes for anemia
HUP0203648A2 (hu)	2003-02-28	Fekély kezelésére alkalmas gyógyászati készítmények
US4455305A (en)	1984-06-19	Composition for the treatment of colitis ulcerosa, enteritis regionalis crohn (morbus crohn), chronic nonspecific colitis and diverticulitis and the use of salicylazobenzoic acid for the preparation of such compositions
HUP0100853A2 (hu)	2001-10-28	Fekély kezelésére alkalmas nitrátsók és ilyen vegyületeket tartalmazó gyógyászati készítmények
CA2398898C (en)	2010-03-30	Therapeutic or preventive agent for digestive system diseases containing a diaminotrifluoromethylpyridine derivative
JPS58113129A (ja)	1983-07-05	変異原性抑制剤
EP2262501A2 (de)	2010-12-22	Behandlung von sepsis mit 5-ethyl-1-phenyl-2(1h)-pyridon und neue synthesemethoden
EP0787494B1 (de)	2004-06-09	Verwendung eines Rifamycin-Derivates zur Herstellung eines Medikamentes zur Behandlung von Krankheiten verursacht durch Helicobacter pylori-Infektionen
TW200400964A (en)	2004-01-16	Antiparasitic artemisinin derivatives (endoperoxides)
KR20230040910A (ko)	2023-03-23	도코사헥사엔산을 포함하는 주의력 결핍 과잉행동장애 치료 또는 예방용 조성물
US3459854A (en)	1969-08-05	Tetracycline cyclohexyl sulphamate and process for preparation
US3065136A (en)	1962-11-20	Treatment of vascular diseases with 2-aminoethanol-1-nitrate salt of p-toluene sulfonic acid
Heseltine et al.	1959	Some pharmacological and microbiological properties of chlorhydroxyquinoline and related compounds
JPS6411616B2 (de)	1989-02-27
US3155579A (en)	1964-11-03	Therapeutic composition for the treatment of disturbances of the water metabolism characterized by an insufficient elmination of water
EP1769796A1 (de)	2007-04-04	Bis(1-Aryl-5-Tetrazolyl)Methan Derivate enthaltende Antibiotika
JPH0446124A (ja)	1992-02-17	抗潰瘍剤
JPS63179826A (ja)	1988-07-23	発癌プロモ−タ−抑制剤
JPH03130223A (ja)	1991-06-04	腫瘍発生予防剤
JPS63208519A (ja)	1988-08-30	発癌促進物質抑制剤
JP3949219B2 (ja)	2007-07-25	抗原虫剤
US3053731A (en)	1962-09-11	Therapeutic composition containing 4, 6-dimethyl-3-pyridazone and process of inducing hypnosis and tranquilization therewith
JP4044227B2 (ja)	2008-02-06	グリシンベタインからなる抗変異原性組成物